Medtech Trends 2026: What Global Shifts in Pricing, Care Settings and Platforms Mean for ASEAN

Subtitle: Five structural forces reshaping global medical technology — from mainland China's procurement reform to platform-based competition — carry distinct consequences for Southeast Asia's healthcare systems, manufacturing base and digital health sector.

Global medical technology is entering a period of accelerated structural change, according to Clarivate's Medtech Trends to Watch 2026. The analysis identifies five forces shaping how device makers compete and where growth is expected to occur: mainland China's expanding volume-based procurement (VBP) programme, the migration of procedures into outpatient and ambulatory surgical centre (ASC) settings, global trade and supply chain pressure, the rapid adoption of GLP-1 therapies, and the rise of enabling technologies that are pushing competition toward integrated platforms.

While much of the published analysis centres on the United States, Europe and mainland China, the underlying dynamics are not contained within those markets. Southeast Asia — with its combined population, expanding digital infrastructure, growing chronic disease burden and increasingly consequential role in global device and electronics manufacturing — sits directly in the path of several of these shifts.

1. Mainland China's VBP expansion and the pricing ripple across Asia

Mainland China's latest national VBP round is described as one of the most consequential changes in global medtech pricing. Originally designed to widen patient access and curb device costs, the programme has evolved into a market-structuring mechanism, with new rules introducing more sophisticated anchor-price logic, deeper price compression and allocation systems that favour domestic manufacturers.

For multinational device companies, VBP is no longer a localized policy question. It influences expectations around price, volume and competitive positioning in markets well beyond mainland China.

For ASEAN, three consequences are worth tracking. First, multinationals facing compressed margins in China may reassess where they allocate commercial resources, and mid-sized ASEAN markets with less aggressive price controls could receive greater attention — even where volumes are smaller. Second, domestic Chinese manufacturers seeking export growth may look to Southeast Asia, intensifying competition in price-sensitive segments such as consumables, imaging and monitoring equipment. Third, hospital group purchasing organizations and public procurement bodies in the region may face pressure to demonstrate value through their own reference pricing, particularly in markets with large public health budgets.

2. Care is migrating out of the hospital — and device design must follow

The continued shift of procedures from inpatient hospitals to outpatient departments and ASCs remains one of the defining medtech trends. In the United States, the Centers for Medicare & Medicaid Services' 2026 Hospital Outpatient Prospective Payment System and ASC Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list, opening the door for higher-acuity procedures such as cardiac ablation to move into lower-cost settings where clinically appropriate.

That pattern builds on long-running migration in orthopaedics and general surgery, where ambulatory centres have become central to growth strategies for both providers and manufacturers.

The ASEAN read-across is less about replication than about direction of travel. The region's payer mix is dominated by out-of-pocket spending and public insurance schemes rather than a single large state payer, so the migration is uneven. Day-surgery capacity is expanding in Singapore, Malaysia and Thailand, often alongside medical tourism offerings, while other markets remain concentrated on inpatient care.

The strategic implication is similar: devices designed for hospital-scale infrastructure, high capital cost and specialist surgical teams may fit less well into smaller, cost-conscious, distributed care settings. Portability, simplified workflows, remote support and consumable economics become more important commercial variables.

3. Supply chain resilience is redrawing manufacturing geography

Tariff exposure, geopolitical factors and fluctuating material costs are challenging long-standing assumptions about where and how devices should be produced. Companies are diversifying sourcing, re-evaluating business strategies and pursuing more flexible multi-region manufacturing footprints. Larger manufacturers are using scale, integration and technology investment to buffer against volatility.

This is arguably the trend with the most direct ASEAN relevance. The region already hosts substantial electronics and precision manufacturing capacity, and several governments have active programmes to move up the value chain into medical devices and life sciences components. Singapore functions as a regional headquarters, research and high-value manufacturing hub, while Malaysia, Vietnam, Thailand, Indonesia and the Philippines compete for component and assembly work.

Realizing that opportunity depends on factors beyond labour cost: quality management systems, cleanroom and sterilization capacity, regulatory approval pathways, and the ability to serve multiple markets. Regional harmonization efforts — including the ASEAN Medical Device Directive framework and national regulator alignment — reduce friction but remain a work in progress. Supply chain diversification decisions are also sticky: once qualification and validation are completed in a new location, production tends to remain there.

4. GLP-1 adoption is shifting demand across adjacent categories

The rapid uptake of glucagon-like peptide-1 receptor agonists is altering how patients and clinicians approach weight management and related comorbidities. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1 therapies have expanded quickly in popularity, changing referral patterns and influencing demand for devices across adjacent categories.

The impact is not uniform. Certain bariatric procedures face sharper volume pressure than others, and downstream effects spanning diabetes care, sleep apnoea and cardiovascular monitoring are only beginning to emerge.

For ASEAN, the trend intersects with a rising burden of obesity, diabetes and metabolic disease, alongside questions of access and affordability that differ sharply between higher-income and emerging markets. Where GLP-1 availability expands, demand for continuous monitoring, remote patient management and digital adherence tools is likely to grow in parallel — much of it delivered through mobile-first platforms rather than traditional clinic infrastructure. Insurance and public reimbursement decisions will determine how quickly that shift materializes.

5. Enabling technologies are pushing competition toward platforms

Robotics, imaging, navigation and digital workflow software are no longer adjuncts to procedures. They are becoming central to integrated ecosystems that support clinical planning, surgical execution and postoperative care. Companies are investing in platform architectures intended to anchor entire service lines, deepen customer relationships and unlock data-driven value propositions, while emerging open-platform systems add flexibility and new competitive dynamics.

In Southeast Asia, this trend overlaps directly with digital economy priorities. Smart hospital initiatives, AI-assisted diagnostics, teleradiology, cloud-hosted clinical software and remote monitoring all depend on the same foundations: reliable connectivity, data centre capacity, interoperability standards and cybersecurity maturity. The region's digital infrastructure build-out — from data centres and 5G deployment to subsea cable investment — makes these capabilities more feasible than a decade ago, but clinical adoption still depends on procurement capacity, workforce training and data governance clarity.

Regional Impact

• Digital economy: Platform-based medtech competition accelerates demand for cloud, connectivity and health data infrastructure across ASEAN, reinforcing the region's broader digital transformation agenda.
• Regional technology competitiveness: Supply chain diversification offers ASEAN an opportunity to capture higher-value medical device manufacturing, provided quality and regulatory systems keep pace.
• Digital infrastructure: Imaging, navigation and remote care workloads place new requirements on data centre capacity, latency and cross-border data handling.
• Cross-border digital trade: Device components, software and services increasingly move across borders, making regulatory harmonization and data transfer rules commercially significant.
• Digital finance and healthcare financing: Expanded chronic disease treatment raises questions about reimbursement models, insurance product design and digital payment integration in health systems.
• Enterprise digital transformation: Hospitals and clinic networks face pressure to modernize workflow software, procurement and supply chain visibility.
• Innovation and startup ecosystem: Digital health, diagnostics and medtech software ventures in the region gain a larger addressable market as care settings diversify.
• Talent: Demand grows for biomedical engineers, regulatory specialists, clinical data scientists and cybersecurity professionals.
• Investment flows: Manufacturing footprint decisions and platform investment cycles influence where regional capital and foreign direct investment land.
• Digital governance: Data protection, AI oversight in clinical settings and device cybersecurity will increasingly shape market access.

Future Outlook

Over the next three to five years, the ASEAN medtech and digital health landscape is likely to be shaped by the interaction of these global forces rather than by any single one.

Pricing reform in mainland China will continue to influence multinational portfolio priorities, potentially making ASEAN markets relatively more attractive for products with defensible differentiation. The migration toward ambulatory and outpatient care will proceed unevenly, driven by private providers, medical tourism and public hospital efficiency programmes rather than by a single regulatory trigger. Manufacturing diversification will continue, with the strongest gains going to markets that can demonstrate regulatory predictability and quality systems.

On the technology side, platform competition will push device makers further into software, data services and long-term service agreements — a shift that requires partnerships with regional cloud, connectivity and systems integration players. GLP-1 adoption will shape demand curves in metabolic care, with monitoring and adherence technologies likely to benefit even where drug access remains constrained.

Regulatory and governance questions will become more consequential. Cross-border data flows, clinical AI validation, device cybersecurity requirements and procurement transparency will determine how quickly regional health systems can adopt platform-based tools. ASEAN's existing digital governance frameworks provide a starting point, but implementation capacity varies widely across member states.

Conclusion

The five medtech trends identified for 2026 are global in origin but local in effect. For Southeast Asia, they represent both competitive pressure and structural opportunity: pressure on price-sensitive device segments and on health systems adapting to new care settings, and opportunity in manufacturing diversification, digital health services and platform-based clinical infrastructure. The pace at which the region converts that opportunity into capability will depend less on technology availability than on regulatory coordination, workforce development and the willingness of health systems to modernize how they buy, deploy and govern medical technology.